Wall Street Week Spending on the Right Things: Future of Cancer, Alzheimer's, Global Debt Cycles
Feb 8, 2025
Albert Bourla, CEO of Pfizer, discusses the company's focus on innovative cancer treatments and the role of AI in drug development. Ray Dalio shares insights on rising global debt, urging smart management for economic stability. Matthew Schrag, a neurologist at Vanderbilt, raises red flags about research integrity in Alzheimer's treatments, stressing the urgent need for accountability in scientific studies. Together, they explore the intersection of healthcare innovation and economic challenges, emphasizing the importance of prioritizing effective therapies.
AI Snips
Chapters
Books
Transcript
Episode notes
Alzheimer's Impact
- Alzheimer's disease impacts millions of Americans, both patients and families.
- The societal and economic costs are massive and projected to rise significantly.
Amyloid Hypothesis Challenges
- A class of Alzheimer's drugs, antibodies, targets amyloid protein, believed to be toxic.
- These drugs remove amyloid but haven't consistently shown cognitive improvement in patients.
Cassava Sciences Investigation
- Dr. Schrag investigated Cassava Sciences' Alzheimer's drug, Simufilam, after concerns arose.
- He found a pattern of data alterations in supporting research from a City University of New York lab.
